Tracer library / [211At]At-MABG
[211At]At-MABG
Also written as [At-211]MABG; At-211-MABG
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 6
What it is
- Compound class
- Benzylguanidine analogue (norepinephrine transporter-targeting radiolabeled benzylguanidine), alpha-emitting analogue of MIBG
- Target / mechanism
- Targets neuroendocrine cells via norepinephrine transporter, similar to MIBG; alpha particle emitter with short path length effectively sterilizing microscopic residual disease PMID 35861867
- Clinical application
- Targeted alpha particle radiotherapy for neuroendocrine tumours including neuroblastoma and pheochromocytoma/paraganglioma PMID 40762934
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| COSMiC-Mini NMP Business Support | custom manifold | SPE | 80.3 ± 4.4 not corrected | 99.0 ± 0.7 | mTMSBG…mTMSBG (1-(3-(Trimethylsilyl)benzyl)guanidine) ABX | 40762934 2025 EJNMMI Radiopharm Chem a general-purpose automated radiosynthesiser, COSMiC-Mini (NMP Business Support Co., Ltd., Hyogo, Japan) - The radiochemical yield and purity were 80.3 ± 4.4% (decay-corrected RCY: 84.0 ± 4.5%) |
| COSMiC-Mini NMP Business Support | custom manifold | SPE | 72.6 ± 13.6 not corrected | >98 | mTMSBG…mTMSBG (1-(3-(Trimethylsilyl)benzyl)guanidine) ABX | 40762934 2025 EJNMMI Radiopharm Chem a general-purpose automated radiosynthesiser, COSMiC-Mini (NMP Business Support Co., Ltd., Hyogo, Japan) - RCYs showing no significant change (RCY: 72.6 ± 13.6%, decay-corrected RCY: 76.1 ± 14.3%, n = 4) |
| COSMiC-Mini NMP Business Support | custom manifold | SPE | 80.3 ± 4.4 not corrected | 99.0 ± 0.7 | 1-(3-(Trimethylsilyl)benzyl)guanidine…1-(3-(Trimethylsilyl)benzyl)guanidine (mTMSBG) ABX | 40762934 2025 EJNMMI Radiopharm Chem COSMiC-Mini automated synthesiser - The radiochemical yield and purity were 80.3 ± 4.4% (decay-corrected RCY: 84.0 ± 4.5%) and 99.0 ± 0.7%, respectively (n = 6) |
| COSMiC-Mini NMP Business Support | custom manifold | SPE | 72.6 ± 13.6 not corrected | >98 | 1-(3-(Trimethylsilyl)benzyl)guanidine…1-(3-(Trimethylsilyl)benzyl)guanidine (mTMSBG) ABX | 40762934 2025 EJNMMI Radiopharm Chem COSMiC-Mini automated synthesiser - its effect was minimal, with RCYs showing no significant change (RCY: 72.6 ± 13.6%, decay-corrected RCY: 76.1 ± 14.3%, n = 4) |
| — | custom manifold | HPLC | 70% | >95% | Resin-supported MBG precursor Progenics Pharmaceuticals, Inc., a Lantheus company | 35861867 2022 Clin Cancer Res |
| Manual synthesis | — | — | — | — | — | 9649115 1998 Br J Cancer Using a no-carrier-added synthesis route, we produced 123I-, 125I-, 131I- and 211At-labelled benzylguanidines |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- ABX, Progenics Pharmaceuticals, Inc.
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [211At]At-MABG, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 15 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 35861867: 'Here we investigated the safety and antitumor activity [211At]MABG in preclinical models of neuroblastoma.'.